Victory Capital Management Inc. Has $9.05 Million Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Victory Capital Management Inc. reduced its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 28.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 216,036 shares of the company's stock after selling 84,935 shares during the period. Victory Capital Management Inc. owned about 0.43% of PROCEPT BioRobotics worth $9,054,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of PROCEPT BioRobotics by 10.4% during the third quarter. Vanguard Group Inc. now owns 4,074,891 shares of the company's stock valued at $133,697,000 after acquiring an additional 385,271 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of PROCEPT BioRobotics during the third quarter worth $26,404,000. American Century Companies Inc. raised its position in shares of PROCEPT BioRobotics by 14.2% in the third quarter. American Century Companies Inc. now owns 655,295 shares of the company's stock valued at $21,500,000 after buying an additional 81,534 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in shares of PROCEPT BioRobotics by 49.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,300 shares of the company's stock worth $432,000 after buying an additional 3,400 shares in the last quarter. Finally, Dark Forest Capital Management LP acquired a new position in PROCEPT BioRobotics during the third quarter worth about $583,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Stock Performance

PRCT traded up $1.81 during trading on Tuesday, reaching $65.31. The company's stock had a trading volume of 497,613 shares, compared to its average volume of 542,298. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.44 and a current ratio of 8.52. PROCEPT BioRobotics Co. has a 52-week low of $24.83 and a 52-week high of $66.08. The company has a market capitalization of $3.36 billion, a price-to-earnings ratio of -30.81 and a beta of 0.95. The company's fifty day moving average price is $52.22 and its 200-day moving average price is $45.59.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.04. The business had revenue of $44.50 million for the quarter, compared to analyst estimates of $41.58 million. PROCEPT BioRobotics had a negative net margin of 66.12% and a negative return on equity of 41.35%. The company's quarterly revenue was up 82.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.63) earnings per share. On average, equities analysts forecast that PROCEPT BioRobotics Co. will post -1.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on PRCT shares. TD Cowen raised their price objective on PROCEPT BioRobotics from $65.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, May 6th. Truist Financial lifted their price target on shares of PROCEPT BioRobotics from $63.00 to $72.00 and gave the stock a "buy" rating in a research note on Thursday, May 2nd. Finally, Piper Sandler boosted their target price on shares of PROCEPT BioRobotics from $67.00 to $75.00 and gave the stock an "overweight" rating in a research note on Monday, May 6th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, PROCEPT BioRobotics currently has an average rating of "Buy" and an average target price of $61.20.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 3,435 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $46.67, for a total transaction of $160,311.45. Following the transaction, the chief financial officer now directly owns 49,416 shares of the company's stock, valued at $2,306,244.72. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, EVP Alaleh Nouri sold 30,432 shares of the business's stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $62.97, for a total transaction of $1,916,303.04. Following the completion of the transaction, the executive vice president now owns 62,472 shares in the company, valued at approximately $3,933,861.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin Waters sold 3,435 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $46.67, for a total transaction of $160,311.45. Following the completion of the transaction, the chief financial officer now directly owns 49,416 shares in the company, valued at approximately $2,306,244.72. The disclosure for this sale can be found here. Insiders have sold a total of 72,651 shares of company stock worth $4,168,073 in the last quarter. 17.40% of the stock is owned by insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).